Contineum Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Hello, everyone, and thanks for joining us here at the Goldman Sachs Global Health Care Conference. We're thrilled to have on stage with me today the Chief Executive Officer and President for Continuum Therapeutics, Carmine Stengone.
Questions & Answers
And maybe I'll turn it first to you, if you could just kind of high-level discuss the clinical catalyst you guys have ahead for the year and where investors should be kind of focused for the remainder of 2026?
Yeah, absolutely. Corinne, nice to meet you, and thanks to the Goldman team for allowing us to join on the fireside.
This is a catalyst-rich year for us. So I think the main focus is going to be around LPA1.
So we have what we believe is the best-in-class LPA-1 receptor antagonist.
The focus for this, the big focus for this year is clinical execution on our Phase II study in idiopathic pulmonary
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
